A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > BUSINESS
BUSINESS
- GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
- Nippon Chemiphar Revises Business Forecasts for 1st Half of FY2012
October 26, 2011
- Perpetuation of Premium for New Drug Development Discussed at IMS Japan Symposium
October 26, 2011
- Wakamoto Revises the Full-Year Consolidated Forecasts Expecting Deficit Reduction
October 25, 2011
- MTPC Introduces 3-level Priority for Priority Products
October 25, 2011
- “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
- Mochida Upwardly Revises Business Forecasts for 1st Half of FY2012
October 25, 2011
- Biggest Challenge Is Decline in R&D Productivity: President Hasegawa of Takeda
October 25, 2011
- IBL Signs Licensing Contact with US Firm for Lung Cancer Type Identifying Antibody
October 25, 2011
- Daiichi Sankyo, AZ Apply for Additional Indication for Nexium for Prevention of GU, DU in Patients Given Low-Dose Aspirin
October 25, 2011
- Pfizer Japan to Split Up Domestic Manufacturing Sector to Establish New Company
October 25, 2011
- Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
- CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
- Sales Remain Unchanged due to Domestic Market Slump Affected by Quake: Chugai Jan-Sep 2011
October 24, 2011
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
- SymBio’s Bendamustine Gets NDA Approval in Taiwan
October 24, 2011
- US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug
October 24, 2011
- Otsuka Confirms Efficacy of Rotigotine for RLS in Domestic PIII Clinical Study
October 21, 2011
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…